Evidence map›Paper›PMID 25078629›Full record

ReviewArtificial cells, nanomedicine, and biotechnology2016

Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?

Wenya Yu, Lu Wang, Na Han, Xiayan Zhang, Tanmay Mahapatra, Sanchita Mahapatra, Giridhar R Babu, Weiming Tang, Roger Detels, Jinkou Zhao

Abstract readReview
In one paragraph

Review in Artificial cells, nanomedicine, and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenya Yua Shijiazhuang Center for Disease Control and Prevention , Shijia Zhuang , China.
Lu Wangb National Center for AIDS/STD Control and Prevention, Chinese Centre for Disease Control and Prevention , Beijing , China.
Na Hanc Institute of Clinical Molecular Biology, Peking University People's Hospital , Beijing China.
Xiayan Zhangb National Center for AIDS/STD Control and Prevention, Chinese Centre for Disease Control and Prevention , Beijing , China.
Tanmay Mahapatrad Mission Arogya Health and Information Technology Research Foundation , Kolkata , India.
Sanchita Mahapatrad Mission Arogya Health and Information Technology Research Foundation , Kolkata , India.
Giridhar R Babue Public Health Foundation of India, Indian Institutes of Public Health , Hyderabad, Bengaluru Campus, Bengaluru , India.
Weiming Tangf University of North Carolina , Project-China, Guangzhou , China.
Roger Detelsg Department of Epidemiology , Fielding School of Public Health, University of California , Los Angeles , CA , USA.
Jinkou Zhaoh Impact Results and Evaluation Department, The Global Fund to Fight AIDS , Tuberculosis and Malaria, Geneva , Switzerland.

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
UNC-South China STD Research Training CenterD43TW009532 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COHEN, MYRON SCOTT, TUCKER, JOSEPH DAVID · 2013 to 2017
$1.3M
FIC NIH HHS D43 TW009532NCATS NIH HHS UL1 TR000124NIAID NIH HHS P30 AI028697NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

Antiretroviral drugs are being tried as candidates for the pre-exposure prophylaxis (PrEP) against HIV for a considerable period, due to their potential for immediate inhibition of viral replication. Discrepancies in the findings called for a critical review of the relevant efforts and their outcomes. A systematic literature search identified 143 eligible articles of which only 5 reported complete findings while another 11 were still on-going. Observed moderate efficacy and good safety profile seemed to identify PrEP as a promising step for minimizing the spread of HIV to relatively unaffected population and controlling the epidemic among high risk population groups. But the duration of this efficacy was found to depend heavily on the availability, adherence and other related issues like cost, political commitment, ethical consideration etc. To prevent potential cultural and behavioral modifications, proper pre-administration counseling also seemed critical for the success of PrEP as a cost-effective intervention with adequate coverage.

Indexed as

Anti-HIV AgentsCost-Benefit AnalysisDrug CombinationsEmtricitabineFemaleHIV InfectionsHumansMalePatient CompliancePre-Exposure ProphylaxisRandomized Controlled Trials as TopicRisk-TakingSexual BehaviorTenofovirTreatment OutcomeAnti-HIV AgentsDrug CombinationsEmtricitabineTenofovirantiretroviral therapycontrolling the HIV epidemicHIV preventionpre-exposure prophylaxisprevention of HIV spread

Identifiers

PMID25078629
PMCPMC4312541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.